Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 146

1.

Development of aqueous-based multi-herbal combination using principal component analysis and its functional significance in HepG2 cells.

Kaur P, Robin, Mehta RG, Singh B, Arora S.

BMC Complement Altern Med. 2019 Jan 15;19(1):18. doi: 10.1186/s12906-019-2432-9.

2.

Progression of conventional hepatic cell culture models to bioengineered HepG2 cells for evaluation of herbal bioactivities.

Kaur P, Robin, Mehta RG, Arora S, Singh B.

Biotechnol Lett. 2018 Jun;40(6):881-893. doi: 10.1007/s10529-018-2547-y. Epub 2018 Apr 3. Review.

PMID:
29616383
3.

Suppression of Breast Cancer Cell Proliferation by Selective Single-Domain Antibody for Intracellular STAT3.

Singh S, Murillo G, Chen D, Parihar AS, Mehta RG.

Breast Cancer (Auckl). 2018 Jan 3;12:1178223417750858. doi: 10.1177/1178223417750858. eCollection 2018.

4.

Crosstalk between the vitamin D receptor (VDR) and miR-214 in regulating SuFu, a hedgehog pathway inhibitor in breast cancer cells.

Alimirah F, Peng X, Gupta A, Yuan L, Welsh J, Cleary M, Mehta RG.

Exp Cell Res. 2016 Nov 15;349(1):15-22. doi: 10.1016/j.yexcr.2016.08.012. Epub 2016 Sep 28.

PMID:
27693451
5.

LiSIs: An Online Scientific Workflow System for Virtual Screening.

Kannas CC, Kalvari I, Lambrinidis G, Neophytou CM, Savva CG, Kirmitzoglou I, Antoniou Z, Achilleos KG, Scherf D, Pitta CA, Nicolaou CA, Mikros E, Promponas VJ, Gerhauser C, Mehta RG, Constantinou AI, Pattichis CS.

Comb Chem High Throughput Screen. 2015;18(3):281-95.

PMID:
25747448
6.

Differential roles of ERα and ERβ in normal and neoplastic development in the mouse mammary gland.

Mehta RG, Hawthorne M, Mehta RR, Torres KE, Peng X, McCormick DL, Kopelovich L.

PLoS One. 2014 Nov 18;9(11):e113175. doi: 10.1371/journal.pone.0113175. eCollection 2014.

7.

Inhibition of proliferation and induction of autophagy by atorvastatin in PC3 prostate cancer cells correlate with downregulation of Bcl2 and upregulation of miR-182 and p21.

Peng X, Li W, Yuan L, Mehta RG, Kopelovich L, McCormick DL.

PLoS One. 2013 Aug 1;8(8):e70442. doi: 10.1371/journal.pone.0070442. Print 2013.

8.

Deguelin action involves c-Met and EGFR signaling pathways in triple negative breast cancer cells.

Mehta R, Katta H, Alimirah F, Patel R, Murillo G, Peng X, Muzzio M, Mehta RG.

PLoS One. 2013 Jun 10;8(6):e65113. doi: 10.1371/journal.pone.0065113. Print 2013.

9.

Efficacy and mechanism of action of Deguelin in suppressing metastasis of 4T1 cells.

Mehta RR, Katta H, Kalra A, Patel R, Gupta A, Alimirah F, Murillo G, Peng X, Unni A, Muzzio M, Mehta RG.

Clin Exp Metastasis. 2013 Oct;30(7):855-66. doi: 10.1007/s10585-013-9585-6. Epub 2013 May 5.

10.

Vitamin D and breast cancer: emerging concepts.

Mehta RG, Peng X, Alimirah F, Murillo G, Mehta R.

Cancer Lett. 2013 Jun 28;334(1):95-100. doi: 10.1016/j.canlet.2012.10.034. Epub 2012 Nov 8. Review.

PMID:
23142286
11.

PPARγ antagonist GW9662 induces functional estrogen receptor in mouse mammary organ culture: potential translational significance.

Mehta RG, Peng X, Roy S, Hawthorne M, Kalra A, Alimirah F, Mehta RR, Kopelovich L.

Mol Cell Biochem. 2013 Jan;372(1-2):249-56. doi: 10.1007/s11010-012-1466-9. Epub 2012 Sep 24.

PMID:
23001870
12.

Efficacy and mechanism of action of Proellex, an antiprogestin in aromatase overexpressing and Letrozole resistant T47D breast cancer cells.

Gupta A, Mehta R, Alimirah F, Peng X, Murillo G, Wiehle R, Mehta RG.

J Steroid Biochem Mol Biol. 2013 Jan;133:30-42. doi: 10.1016/j.jsbmb.2012.08.004. Epub 2012 Aug 23.

PMID:
22939887
13.

Crosstalk between the peroxisome proliferator-activated receptor γ (PPARγ) and the vitamin D receptor (VDR) in human breast cancer cells: PPARγ binds to VDR and inhibits 1α,25-dihydroxyvitamin D3 mediated transactivation.

Alimirah F, Peng X, Yuan L, Mehta RR, von Knethen A, Choubey D, Mehta RG.

Exp Cell Res. 2012 Nov 15;318(19):2490-7. doi: 10.1016/j.yexcr.2012.07.020. Epub 2012 Aug 4.

PMID:
22884583
14.

Estrogen receptor-β protects against colitis-associated neoplasia in mice.

Saleiro D, Murillo G, Benya RV, Bissonnette M, Hart J, Mehta RG.

Int J Cancer. 2012 Dec 1;131(11):2553-61. doi: 10.1002/ijc.27578. Epub 2012 Apr 27.

15.

Regulation of CYP24 splicing by 1,25-dihydroxyvitamin D₃ in human colon cancer cells.

Peng X, Tiwari N, Roy S, Yuan L, Murillo G, Mehta RR, Benya RV, Mehta RG.

J Endocrinol. 2012 Feb;212(2):207-15. doi: 10.1530/JOE-11-0305. Epub 2011 Nov 8.

PMID:
22068926
16.

Modeling the cellular impact of nanoshell-based biosensors using mouse alveolar macrophage cultures.

Swarup VP, Huang Y, Murillo G, Saleiro D, Mehta RG, Bishnoi SW.

Metallomics. 2011 Nov;3(11):1218-26. doi: 10.1039/c1mt00089f. Epub 2011 Aug 19.

PMID:
21858295
17.

Androgen Receptor regulation of Vitamin D receptor in response of castration-resistant prostate cancer cells to 1α-Hydroxyvitamin D5 - a calcitriol analog.

Mooso B, Madhav A, Johnson S, Roy M, Moore ME, Moy C, Loredo GA, Mehta RG, Vaughan AT, Ghosh PM.

Genes Cancer. 2010 Nov 16;1(9):927-940.

18.

Functional significance of vitamin D receptor FokI polymorphism in human breast cancer cells.

Alimirah F, Peng X, Murillo G, Mehta RG.

PLoS One. 2011 Jan 24;6(1):e16024. doi: 10.1371/journal.pone.0016024.

19.

Paxillin expression and amplification in early lung lesions of high-risk patients, lung adenocarcinoma and metastatic disease.

Mackinnon AC, Tretiakova M, Henderson L, Mehta RG, Yan BC, Joseph L, Krausz T, Husain AN, Reid ME, Salgia R.

J Clin Pathol. 2011 Jan;64(1):16-24. doi: 10.1136/jcp.2010.075853. Epub 2010 Nov 2.

20.

A 28-amino-acid peptide fragment of the cupredoxin azurin prevents carcinogen-induced mouse mammary lesions.

Mehta RR, Hawthorne M, Peng X, Shilkaitis A, Mehta RG, Beattie CW, Das Gupta TK.

Cancer Prev Res (Phila). 2010 Oct;3(10):1351-60. doi: 10.1158/1940-6207.CAPR-10-0024. Epub 2010 Sep 14.

21.

Enhanced induction of mucin-depleted foci in estrogen receptor {beta} knockout mice.

Saleiro D, Murillo G, Lubahn DB, Kopelovich L, Korach KS, Mehta RG.

Cancer Prev Res (Phila). 2010 Sep;3(9):1198-204. doi: 10.1158/1940-6207.CAPR-10-0044. Epub 2010 Aug 17.

22.

Protection against cellular stress by 25-hydroxyvitamin D3 in breast epithelial cells.

Peng X, Vaishnav A, Murillo G, Alimirah F, Torres KE, Mehta RG.

J Cell Biochem. 2010 Aug 15;110(6):1324-33. doi: 10.1002/jcb.22646.

PMID:
20564226
23.

Functionality of unliganded VDR in breast cancer cells: repressive action on CYP24 basal transcription.

Alimirah F, Vaishnav A, McCormick M, Echchgadda I, Chatterjee B, Mehta RG, Peng X.

Mol Cell Biochem. 2010 Sep;342(1-2):143-50. doi: 10.1007/s11010-010-0478-6. Epub 2010 May 4.

24.

Cancer chemoprevention by natural products: how far have we come?

Mehta RG, Murillo G, Naithani R, Peng X.

Pharm Res. 2010 Jun;27(6):950-61. doi: 10.1007/s11095-010-0085-y. Epub 2010 Mar 18. Review.

PMID:
20238150
25.

Actions of vitamin D are mediated by the TLR4 pathway in inflammation-induced colon cancer.

Murillo G, Nagpal V, Tiwari N, Benya RV, Mehta RG.

J Steroid Biochem Mol Biol. 2010 Jul;121(1-2):403-7. doi: 10.1016/j.jsbmb.2010.03.009. Epub 2010 Mar 7.

26.

Deguelin inhibits growth of breast cancer cells by modulating the expression of key members of the Wnt signaling pathway.

Murillo G, Peng X, Torres KE, Mehta RG.

Cancer Prev Res (Phila). 2009 Nov;2(11):942-50. doi: 10.1158/1940-6207.CAPR-08-0232. Epub 2009 Oct 27.

27.
28.

Efficacy of chemopreventive agents in mouse mammary gland organ culture (MMOC) model: a comprehensive review.

Mehta RG, Naithani R, Huma L, Hawthorne M, Moriarty RM, McCormick DL, Steele VE, Kopelovich L.

Curr Med Chem. 2008;15(27):2785-825. Review.

PMID:
18991637
29.

Antiviral activity of phytochemicals: a comprehensive review.

Naithani R, Huma LC, Holland LE, Shukla D, McCormick DL, Mehta RG, Moriarty RM.

Mini Rev Med Chem. 2008 Oct;8(11):1106-33. Review.

PMID:
18855727
30.

Comprehensive review of cancer chemopreventive agents evaluated in experimental carcinogenesis models and clinical trials.

Naithani R, Huma LC, Moriarty RM, McCormick DL, Mehta RG.

Curr Med Chem. 2008;15(11):1044-71. Review.

PMID:
18473802
31.

25-Hydroxyvitamin D3 is a natural chemopreventive agent against carcinogen induced precancerous lesions in mouse mammary gland organ culture.

Peng X, Hawthorne M, Vaishnav A, St-Arnaud R, Mehta RG.

Breast Cancer Res Treat. 2009 Jan;113(1):31-41. doi: 10.1007/s10549-008-9900-0. Epub 2008 Jan 20.

32.

Molecular mechanisms of resveratrol action in lung cancer cells using dual protein and microarray analyses.

Whyte L, Huang YY, Torres K, Mehta RG.

Cancer Res. 2007 Dec 15;67(24):12007-17.

33.

Advanced rat mammary cancers are growth hormone dependent.

Shen Q, Lantvit DD, Lin Q, Li Y, Christov K, Wang Z, Unterman TG, Mehta RG, Swanson SM.

Endocrinology. 2007 Oct;148(10):4536-44. Epub 2007 Jun 21.

PMID:
17584969
34.

Zapotin, a phytochemical present in a Mexican fruit, prevents colon carcinogenesis.

Murillo G, Hirschelman WH, Ito A, Moriarty RM, Kinghorn AD, Pezzuto JM, Mehta RG.

Nutr Cancer. 2007;57(1):28-37.

PMID:
17516860
35.

Chemopreventive efficacy of 25-hydroxyvitamin D3 in colon cancer.

Murillo G, Matusiak D, Benya RV, Mehta RG.

J Steroid Biochem Mol Biol. 2007 Mar;103(3-5):763-7. Epub 2007 Jan 24.

36.

Ixocarpalactone A isolated from the Mexican tomatillo shows potent antiproliferative and apoptotic activity in colon cancer cells.

Choi JK, Murillo G, Su BN, Pezzuto JM, Kinghorn AD, Mehta RG.

FEBS J. 2006 Dec;273(24):5714-23.

38.

Clinical trials using chemopreventive vitamin D analogs in breast cancer.

Vijayakumar S, Boerner PS, Mehta RR, Packianathan S, Mehta RG, Das Gupta TK.

Cancer J. 2006 Nov-Dec;12(6):445-50. Review.

PMID:
17207311
39.

Overexpression of ER and VDR is not sufficient to make ER-negative MDA-MB231 breast cancer cells responsive to 1alpha-hydroxyvitamin D5.

Peng X, Jhaveri P, Hussain-Hakimjee EA, Mehta RG.

Carcinogenesis. 2007 May;28(5):1000-7. Epub 2006 Nov 27.

PMID:
17130524
40.

Inhibition of estrogen-independent mammary carcinogenesis by disruption of growth hormone signaling.

Zhang X, Mehta RG, Lantvit DD, Coschigano KT, Kopchick JJ, Green JE, Hedayat S, Christov KT, Ray VH, Unterman TG, Swanson SM.

Carcinogenesis. 2007 Jan;28(1):143-50. Epub 2006 Aug 17.

PMID:
16916863
41.

Prohibitin is a novel target gene of vitamin D involved in its antiproliferative action in breast cancer cells.

Peng X, Mehta R, Wang S, Chellappan S, Mehta RG.

Cancer Res. 2006 Jul 15;66(14):7361-9.

42.

Antioxidant xanthones from the pericarp of Garcinia mangostana (Mangosteen).

Jung HA, Su BN, Keller WJ, Mehta RG, Kinghorn AD.

J Agric Food Chem. 2006 Mar 22;54(6):2077-82.

PMID:
16536578
43.

Clinical trials involving vitamin D analogs in prostate cancer.

Vijayakumar S, Mehta RR, Boerner PS, Packianathan S, Mehta RG.

Cancer J. 2005 Sep-Oct;11(5):362-73. Review.

PMID:
16259866
44.

Expression of vitamin D receptor and 25-hydroxyvitamin D3-1{alpha}-hydroxylase in normal and malignant human colon.

Matusiak D, Murillo G, Carroll RE, Mehta RG, Benya RV.

Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2370-6.

45.

Growth inhibition of carcinogen-transformed MCF-12F breast epithelial cells and hormone-sensitive BT-474 breast cancer cells by 1alpha-hydroxyvitamin D5.

Hussain-Hakimjee EA, Peng X, Mehta RR, Mehta RG.

Carcinogenesis. 2006 Mar;27(3):551-9. Epub 2005 Sep 29.

PMID:
16195238
46.

Chemoprevention of chemically-induced mammary and colon carcinogenesis by 1alpha-hydroxyvitamin D5.

Murillo G, Mehta RG.

J Steroid Biochem Mol Biol. 2005 Oct;97(1-2):129-36. Epub 2005 Jul 26.

PMID:
16051482
47.

Resveratrol inhibits rhabdomyosarcoma cell proliferation.

Chow AW, Murillo G, Yu C, van Breemen RB, Boddie AW, Pezzuto JM, Das Gupta TK, Mehta RG.

Eur J Cancer Prev. 2005 Aug;14(4):351-6.

PMID:
16030425
48.

Designing a randomized phase I/II prostate cancer chemoprevention trial using 1alpha-hydroxy-24-ethyl-cholecalciferol, an analogue of vitamin D3.

Packianathan S, Mehta RG, Mehta RR, Hall WH, Boerner PS, Beckett LA, Vijayakumar S.

Cancer J. 2004 Nov-Dec;10(6):357-67.

PMID:
15701267
49.

Inhibition of proliferation and induction of apoptosis by 25-hydroxyvitamin D3-3beta-(2)-Bromoacetate, a nontoxic and vitamin D receptor-alkylating analog of 25-hydroxyvitamin D3 in prostate cancer cells.

Swamy N, Chen TC, Peleg S, Dhawan P, Christakos S, Stewart LV, Weigel NL, Mehta RG, Holick MF, Ray R.

Clin Cancer Res. 2004 Dec 1;10(23):8018-27.

50.

Identification of novel RARbeta2 transcript variants with short 5'-UTRs in normal and cancerous breast epithelial cells.

Peng X, Mehta RG, Tonetti DA, Christov K.

Oncogene. 2005 Feb 10;24(7):1296-301.

PMID:
15558014

Supplemental Content

Loading ...
Support Center